Kornimate/medical-research-clean huggingface dataset:
artificial intelligence-assisted colonoscopy for detection of colon polyps

Conditions: Artificial Intelligence; Colonoscopy

Summary: all subjects shall sign informed consent before screening, and subjects shall be included according to inclusion and exclusion criteria. a total of four endoscopists were included in the study, two in each group of senior endoscopists and two in each group of junior endoscopists. patients were randomly enrolled into the senior endoscopy group and the junior endoscopy group, and received artificial intelligence assisted colonoscopy and conventional colonoscopy successively. the two colonoscopy methods were performed back to back by different endoscopy physicians with the same seniority. all patients were examined and treated according to routine medical procedures. the routine colonoscopy group and the artificial-intelligence-assisted colonoscopy group made detailed records of the patients' withdrawal time, entry time, number of polyps detected, polyp paris classification, polyp size, polyp shape, polyp location and intestinal preparation during the colonoscopy process

this is a prospective randomized clinical study.this study was conducted in the endoscopy center of the nanfang hospital, china. routine bowel preparation consisted of 4 l of polyethylene glycol, given in split doses. colonoscopies were performed with high definition colonoscopes and high-definition monitors. all subjects shall sign informed consent before screening, and subjects shall be included according to inclusion and exclusion criteria. a total of four endoscopists were included in the study, two in each group of senior endoscopists (\>1000 colonoscopies) and two in each group of junior endoscopists ( \<1000 colonoscopies). patients were randomly enrolled into the senior endoscopy group and the junior endoscopy group, and received artificial intelligence assisted colonoscopy and conventional colonoscopy successively. the two colonoscopy methods were performed by different endoscopy physicians back to back with the same seniority. all patients were examined and treated according to routine medical procedures (outpatient patients and inpatients who did not sign the consent form for polypectomy were not resected for the lesions detected during the examination, while inpatients who signed the consent form for polypectomy were left in the original position after the first colonoscopy and removed at the end of the second examination). the routine colonoscopy group and the artificial-intelligence-assisted colonoscopy group made detailed records of the patients' withdrawal time, entry time, number of polyps detected, polyp paris classification, polyp size, polyp shape, polyp location and intestinal preparation during the colonoscopy process.

Eligibility criteria:
inclusion criteria: chinese population aged 18-80 years old; patients voluntarily signed informed consent form; in accordance with the indications of colonoscopy. exclusion criteria: (ibd) history of inflammatory bowel disease; history of colorectal surgery; previous failed colonoscopy; polyposis syndrome; highly suspected colorectal cancer (crc)
the impact of hypothyroidism on tear production and dry eye symptoms: implications for optometric care

Conditions: Dry Eye Syndromes

Summary: this observational cross-sectional study will assess the impact of hypothyroidism on tear production and tear film stability. conducted at dhq hospital dera ghazi khan over six months, the study will recruit 71 participants aged 20-60 years using a non-probability convenience sampling method. patients with confirmed hypothyroidism will undergo tear assessment through the schirmer i test, tear breakup time (tbut) test, and ocular surface disease index (osdi) questionnaire. the schirmer test will measure tear production, while tbut will assess tear film stability.

ocular surface staining and tear osmolarity will further evaluate ocular health. patients with systemic conditions affecting tear production, such as diabetes or rheumatoid arthritis, will be excluded. the collected data will be analyzed to determine the relationship between hypothyroidism and dry eye symptoms, aiding in better management of ocular health in hypothyroid patients. the study aims to provide valuable insights into the association between thyroid dysfunction and tear film abnormalities.

Eligibility criteria:
inclusion criteria: * age between 20-60 years. * confirmed diagnosis of hypothyroidism with thyroid function tests. * no prior history of ocular surgery or significant ocular pathology. exclusion criteria: * use of systemic medications affecting tear production (e.g., antihistamines, diuretics). * other systemic conditions (e.g., diabetes, rheumatoid arthritis). * pregnancy or lactation
testing miglustat administration in subjects with spastic paraplegia 11

Conditions: Hereditary Spastic Paraparesis

Summary: hereditary spastic paraparesis type 11 (spg11) is caused by mutations in the spg11 gene that produces spatacsin, a protein involved in lysosomal function. studies performed in skin cells (fibroblasts) from spg11 patients, mice and zebrafish models of the disease showed that the material accumulated in the lysosomes is made of glycosphingolipids (gsl). miglustat is a drug that inhibits an enzyme called glucosylceramide synthetase (gcs) which is used for the production of gsl. miglustat, therefore, helps to delay the production of gsl. this study aims to collect preliminary data on the safety of miglustat on the spg11 disease and to assess biomarkers.

we will analyze the safety of miglustat

Eligibility criteria:
inclusion criteria: * written signed informed consent; * confirmed diagnosis of spg11; * age \> 13 years; * sprs score ≥ 10 or ≤35; * use of effective contraceptive methods and the performance of pregnancy tests (only fertile subjects). exclusion criteria: * diagnosis of other concomitant neurodegenerative diseases; * outcomes of severe pre- or peri-natal suffering; * age ≤ 13 years; * sprs score ≥ 35 or ≤10; * hypersensitivity or intolerance to miglustat; * participation in other pharmacological studies within 30 days of the first study visit (t0); * the inability to take the drug; * any additional medical conditions; * subjects with severe renal impairment; * refusal to use effective contraceptive methods and the performance of pregnancy tests (only fertile subjects).

Keywords: autophagic lysosome reformation spg11 miglustat lisosomal storage disorders
a 12 week study of qva149 compared to fluticasone/salmeterol (advair) for treatment of copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: study is to show that qva149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation.


Eligibility criteria:
inclusion criteria: - age \>= 40 years, patients with airflow limitation indicated by post-bronchdilation fev1 \>=30% and \ 450 ms, paroxysmal atrial fibrillation, type i or uncontrolled type ii diabetes, history of asthma, copd diagnosis before age 40, receiving treatments not allowed in the study, other concomitant pulmonary diseases. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: copd
anesthesia in patients with mitochondrial disease

Conditions: Mitochondrial Diseases

Summary: this pilot study is a prospective, randomized clinical trial to evaluate the effect of anesthesia in the mitochondrial dysfunction patient.

study subjects undergoing a routine medical care non-emergent procedure will be randomized into three different groups to receive one of the following anesthetic agents; sevoflurane, propofol or dexmedetomidine. the primary outcome of this pilot study is to evaluate and compare the incidence of adverse events in mitochondrial patients undergoing a diagnostic or therapeutic procedure up to 48 hours post anesthesia. the secondary outcome is to compare the metabolic derangements between three study groups by comparing changes in blood sugar, serum ph, serum bicarbonate, serum lactate and serum pyruvate levels before, during and after anesthesia in the groups.

Eligibility criteria:
inclusion criteria: * subjects must fulfill the following inclusion criteria: * subject is informed and given ample opportunity to consider his/her participation and has given his/her written consent. * subject is willing and able to comply with all study requirements. * subject is between 0 - 17 years of age. * subject has been diagnosed with mitochondrial dysfunction based on modified walker criteria. * subject is scheduled to have a non-emergent diagnostic or therapeutic procedure for routine medical care requiring general anesthesia estimated to last at least one hour. * subject is classified asa i - iv exclusion criteria: subjects are not permitted to enroll in the study if any of the following criteria are met: * subject is older than 17 years * subject is pregnant * subject is a nursing female and * subject has participated in the same study within 48 hours * subject is allergic or has had any adverse effect to any of the study agents in the past * anesthesia time is less than one hour * subject is classified asa v

Keywords: mitochondrial diseases sevoflurane dexmedetomidine (precedex®) propofol
factors affecting quality of life in patient with chronic musculoskeletal pain

Conditions: Quality of Life; Chronic Musculoskeletal Disease; Chronic Pain

Summary: this study included patients who applied to the physical therapy and rehabilitation outpatient clinic and were diagnosed with chronic low back pain and osteoarthrosis and met the criteria for participation in the study. demografik datas, pain , functional limitations and quality of life wa evaluated.

when treating diseases, clinicians traditionally aim for pain reduction and functional recovery. this is also true for chronic musculoskeletal diseases. however, the psychosocial support required to improve the general health perception of patients is becoming increasingly important. in clinical practice, it is essential to evaluate the quality of life and general well-being and to evaluate the patient completely biopsychosocially . determining the factors affecting the quality of life is important in terms of contributing to the rehabilitation processes and treatment plans of cmp patients. in this direction, our study aims to examine the factors affecting the quality of life. when treating diseases, clinicians traditionally aim for pain reduction and functional recovery. this is also true for chronic musculoskeletal diseases. however, the psychosocial support required to improve the general health perception of patients is becoming increasingly important. in clinical practice, it is essential to evaluate the quality of life and general well-being and to evaluate the patient completely biopsychosocially . determining the factors affecting the quality of life is important in terms of contributing to the rehabilitation processes and treatment plans of cmp patients. in this direction, our study aims to examine the factors affecting the quality of life.

Eligibility criteria:
inclusion criteria: * aged between 18 and 65 years old * clinical diagnosis of spondilosis and gonarthrosis- * must not be surgical indication exclusion criteria: * history of knee or back surgery * detection of muscle weakness on physical examination * presence of additional neurological disease that will affect the patient's mobilization and cognitive level * presence of cognitive impairment * presence of chronic pain of nonmusculoskeletal origin (gynocological, retroperitoneal, abdominal) * being treated for depression

Keywords: quality of life disabilty chronic musculoskeletal pain
long term nebulised gentamicin in patients with bronchiectasis

Conditions: Bronchiectasis

Summary: the hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation. if given long term this will improve symptoms, pulmonary physiology, exercise capacity and health related quality of life with a reduction in exacerbation frequency and health care utilization.


Eligibility criteria:
inclusion criteria: * bronchiectasis confirmed by hrct of the chest * clinically stable (not requiring antibiotics for at least 4 weeks preceding the study start date) * aged 18-70 * chronic sputum production \> 5 mls for the majority of days in 3 months before enrolment * chronically colonized (on at least 2 occasions in the preceding 12 months) whilst clinically stable * at least two exacerbations in the past year * patients able to tolerate a nebulized gentamicin challenge * fev1 \> 30% predicted * smoking \ 1 year. exclusion criteria: * cystic fibrosis * emphysema on hrct chest * thoracic surgery within the past 1 year * allergic bronchopulmonary aspergillosis * poorly controlled asthma ( \> 20% diurnal variation in peak expiratory flows despite treatment) * unstable angina or uncontrolled congestive cardiac failure * active malignancy * pregnancy or breast feeding * creatinine clearance \< 30 mls/minute * vestibular instability * previous documented intolerance to aminoglycosides

Keywords: nebulised antibiotics non cystic fibrosis bronchiectasis bacterial load inflammation quality of life side effects
screening for atrial fibrillation in patients with cancer: a pilot randomized controlled clinical trial

Conditions: Cancer

Summary: patients with cancer have a higher incidence of af but despite the higher incidence of af in the cancer population, there are no randomized controlled trials (rcts) for af screening in this population. rcts of af screening in the general population have shown that screening can effectively detect af earlier, and helps to identify candidates for appropriate anticoagulation that may lead to improvement in clinical outcomes.

the investigators will conduct an open label, prospective, pilot rct. after informed consent, patients will be randomized 1:1 into screening or usual care. screening will be done at a single time point. patients randomized to screening will undergo a 30-second ecg using the kardia mobile device (alivecor inc, cupertino, ca) paired with an ipad (apple, cupertino, ca). patients randomized to usual care will not receive a screening ecg. primary outcome will be detection of newly diagnosed af by screening vs usual care.

Eligibility criteria:
inclusion criteria: 1. male and female patients age ≥65 with a current diagnosis or history of cancer. 2. patients currently undergoing or history of chemotherapy, radiotherapy or cancer related surgeries will be included. 3. the age is restricted to ≥65 years because prevalence of af is extremely low. . exclusion criteria: 1. known history of atrial fibrillation. 2. non-english-speaking participants will not be enrolled
evaluation of pet/mri using a somatostatin analog tracer as a novel approach to detecting pathology in high risk tb-exposed contacts

Conditions: Tuberculosis, Pulmonary

Summary: pet/mri (positron emission tomography/magnetic resonance imaging) with somatostatin analog tracers has the potential to provide an imaging technique targeting subclinical granulomatous disease in those with latent tuberculosis (tb), allowing identification of individuals who may be at risk of progression to active tb.

granulomas, the hallmark of tb infection, have an increased density of somatostatin receptors. somatostatin analog pet tracers, such as 68ga-dotanoc, bind to somatostatin receptors and are able to detect pulmonary tb lesions using pet/mri. this study aims to better understand the pathology of the spectrum of latent tb using 68ga-dotanoc pet/mri imaging, identifying individuals with subclinical pulmonary tb who may be at risk of progressing to active tb. currently, biomarkers to identify those who are at risk of developing active tb are limited. non-invasive biomarkers for pulmonary lesions are sorely needed and imaging with 68ga-dotanoc pet/mri provides an opportunity to detect subclinical pulmonary disease in those who have been in close contact with smear-positive pulmonary tb.

Eligibility criteria:
inclusion criteria: 1. age 21 years or over 2. close household contact of any patient with newly-diagnosed (within last 2 months) smear positive pulmonary tb (close contact defined as sleeping in the same house for at least one month with a tb patient prior to start of treatment). 3. interferon gamma release assay (igra) positive 4. willing to comply with the study visits and procedures 5. willing and able to provide written informed consent exclusion criteria: 1. previous treatment for tb disease 2. diabetes that is, in the judgment of the investigator, so poorly controlled that it would prevent adequate pet scanning 3. cardiac pacemaker, aneurysm clip or other metallic implant considered unsafe for mri 4. occupation involving substantial exposure to radiation 5. malignancy requiring chemotherapy or radiation 6. known lung disease which may affect interpretation of the scan 7. known chronic kidney disease 8. symptoms, signs and/or previous investigations suggestive of active tb in the opinion of the investigator (cough for \>1 month, cough productive of sputum or blood, shortness of breath, weight loss, night sweats, fever, abnormal examination, chest x-ray findings) 9. women who are currently pregnant or breastfeeding
vascular closure device versus transradial approach in primary percutaneous coronary intervention

Conditions: Myocardial Infarction; Complications; Device, Vascular; Injury of Radial Artery; Injury; Blood Vessel, Femoral, Artery

Summary: primary percutaneous coronary intervention represents the gold standard for the treatment of st-segment-elevation acute myocardial infarction. however, periprocedural bleedings are associated with an increased risk of mortality, re-infarction, and stroke. although the prognostic value of access site related bleeding complications is still debated, transradial approach is associated with better short-term outcomes and reduced hospital stay as compared to transfemoral approach. the investigators aimed to compare transradial approach with transfemoral approach with systematic achievement of hemostasis by the implantation of a vascular closure device in a national multicentre randomized clinical trial.


Eligibility criteria:
inclusion criteria: * st-segment elevation acute myocardial infarction patients during the first 12 hours of sympton onset; * intention to perform primary percutaneous coronary intervention; * signed informed consent; * patient eligible for transradial and transfemoral primary percutaneous coronary intervention, being pre-requisites: (a) familiarity of the operator with the radial and femoral techniques using vascular closure devices, (b) agreement of the operator to use the access route determined by the randomization process. exclusion criteria: * less than 18 years of age; * pregnancy; * chronic use of vitamin k antagonists or direct thrombin inhibitors, or oral xa-factor antagonists; * hypersensitivity to antiplatelet and/or anticoagulant drugs; * active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance \< 30 ml/min, platelets count \< 100.000 mm3); * uncontrolled systemic hypertension; * cardiogenic shock; * previous myocardial revascularization surgery with ≥ 1 internal mammary or radial artery graft; * documented chronic peripheral arterial disease preventing the use of the femoral technique; * severe concomitant disease with life expectancy below 12 months; * participation in drug or devices investigative clinical trials in the last 30 days; * medical, geographic or social conditions impairing the participation in the study or inability to understand and sign the informed consent term.

Keywords: vascular closure devices transradial approach transfemoral approach
genistein in treating patients with localized prostate cancer who are planning to undergo radical prostatectomy

Conditions: Prostate Cancer

Summary: rationale: genistein may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. purpose: phase ii trial to study the effectiveness of genistein in treating patients with localized prostate cancer who are planning to undergo radical prostatectomy.

objectives: * determine the toxicity of genistein in patients with localized prostate cancer treated with radical prostatectomy. * determine the decrease, if any, of prostate-specific antigen-positive cells in the operative field of patients treated with this drug. * determine the quality of life of patients treated with this drug. outline: patients receive 1 of 2 treatment regimens. * group a: patients receive oral genistein once daily for 1-2 months, undergo radical prostatectomy, and then continue oral genistein once daily for 1-2 months afterward (for a total of 3 months of therapy). * group b: patients undergo radical prostatectomy. beginning 1 month after surgery, patients receive genistein as in arm i for 3 months. quality of life is assessed at baseline and at 1 and 3 months after surgery. patients are followed every 3 months. projected accrual: a total of 88 patients (44 patients per treatment group) will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * diagnosis of localized prostate cancer * diagnosed within the past 6 months * t1 or t2 disease * gleason score 5-8 * prostate-specific antigen no greater than 20 ng/ml * radical prostatectomy planned patient characteristics: age * 18 and over performance status * ecog 0-1 life expectancy * more than 2 years hematopoietic * hemoglobin greater than 9.0 g/dl * platelet count greater than 100,000/mm\^3 * absolute neutrophil count greater than 1,000/mm\^3 hepatic * sgpt and sgot less than 3 times normal * bilirubin less than 3 mg/dl (less than 1.5 times normal) (patients with an elevated bilirubin due to a familial defect in bilirubin metabolism will be considered on an individual basis) renal * creatinine less than 2.0 mg/dl cardiovascular * no venous thrombosis within the past year other * patients must use effective barrier contraception * no other medical condition that would preclude study therapy * no known soy intolerance prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * no concurrent hormonal therapy for prostate cancer radiotherapy * not specified surgery * see disease characteristics other * no concurrent soy supplements * no concurrent foods high in genistein * no concurrent active therapy for neoplastic disorders

Keywords: stage i prostate cancer stage ii prostate cancer
efficacy and safety of rv4104a ointment in onychomycosis

Conditions: Onychomycosis

Summary: the purpose of the study is to evaluate the efficacy of rv4104a ointment versus bifonazole-urea ointment for the complete removal of the clinically infected nail plate area in patients with toenail onychomycosis.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of distal-lateral or lateral subungual onychomycosis of one great toenail (the target nail) * target nail plate showing ≥ 12.5% of clinically infected area * patient must have at least 2 mm of the proximal end of the target nail free of infection * target nail infection due exclusively to a dermatophyte (from both positive direct microscopy examination and positive fungal culture as reported by the central mycological laboratory) exclusion criteria: * patient with more than 2 affected toenails * patient with psoriasis, lichen planus or other abnormalities that could result in clinically abnormal toenail(s) * patient with moccasin-type tinea pedis * patient who has received systemic antifungal therapy or topical antifungal nail lacquer within 3 months or any other topical antifungal therapy applied to the feet or toenails within 2 months prior to screening visit